Literature DB >> 8912176

Spinal muscular atrophies: recent insights and impact on molecular diagnosis.

C Brahe1, E Bertini.   

Abstract

Spinal muscular atrophies (SMA) are a group of motor neuron diseases characterized by degeneration of anterior horn cells of the spinal cord and by muscular atrophy. Childhood-onset SMA is one of the most frequent autosomal recessive diseases and a leading cause of infant mortality. The underlying biochemical defect of SMA is unknown. Recently two genes have been isolated from the critical region at 5q13, the survival motor neuron (SMN) gene and the neuronal apoptosis inhibitor protein (NAIP) gene. Both genes are frequently deleted in SMA patients. NAIP is deleted in at least 45% of severely affected patients but less frequently in the milder forms. Homozygous deletions of exon 7 of SMN are found in approximately 95% of patients independently of clinical severity. A few point mutations and microdeletions in SMN have also been reported. This high frequency of deletions makes SMN analysis an important molecular diagnostic tool for childhood-onset SMA and greatly facilitates prenatal diagnosis. SMN analysis has also proven useful for the diagnosis of adult-onset SMA and variant forms. Although questions such as phenotype-genotype correlation must still be solved, the isolation of SMN and adjacent genes constitutes an important step towards the understanding of the molecular basis of the disease.

Entities:  

Mesh:

Year:  1996        PMID: 8912176     DOI: 10.1007/s001090050059

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  6 in total

Review 1.  The wobbler mouse: a neurodegeneration jigsaw puzzle.

Authors:  Séverine Boillée; Marc Peschanski; Marie-Pierre Junier
Journal:  Mol Neurobiol       Date:  2003-08       Impact factor: 5.590

2.  SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; Charles B Scott; Thomas O Crawford; Louise R Simard; Sandra P Reyna; Kristin J Krosschell; Gyula Acsadi; Bakri Elsheik; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan L Sorenson; Jo Anne Maczulski; Mark B Bromberg; Gary M Chan; John T Kissel
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

Review 3.  Spinal muscular atrophy: untangling the knot?

Authors:  I Biros; S Forrest
Journal:  J Med Genet       Date:  1999-01       Impact factor: 6.318

4.  Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy.

Authors:  Juliane Ramser; Mary Ellen Ahearn; Claus Lenski; Kemal O Yariz; Heide Hellebrand; Michael von Rhein; Robin D Clark; Rita K Schmutzler; Peter Lichtner; Eric P Hoffman; Alfons Meindl; Lisa Baumbach-Reardon
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

5.  SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy.

Authors:  John T Kissel; Charles B Scott; Sandra P Reyna; Thomas O Crawford; Louise R Simard; Kristin J Krosschell; Gyula Acsadi; Bakri Elsheik; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan Sorenson; Jo Anne Maczulski; Mark B Bromberg; Gary M Chan; Kathryn J Swoboda
Journal:  PLoS One       Date:  2011-07-06       Impact factor: 3.240

6.  Phase II open label study of valproic acid in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; Charles B Scott; Sandra P Reyna; Thomas W Prior; Bernard LaSalle; Susan L Sorenson; Janine Wood; Gyula Acsadi; Thomas O Crawford; John T Kissel; Kristin J Krosschell; Guy D'Anjou; Mark B Bromberg; Mary K Schroth; Gary M Chan; Bakri Elsheikh; Louise R Simard
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.